Company / Shareholders' Equity
Monopar Therapeutics Shareholders' Equity History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$137.8M
FY2025
5-year range
$5.6M / $137.8M
FY2021-FY2025
Trend
+2366.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity changed +2367% YoY in FY2025, a notable deviation from the 5-year average annual change of +515%.
Based on SEC 10-K filings.
$138M in FY2025.
Improved from $10M to $138M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, shareholders' equity increased 2366.6% year-over-year.
- Lowest shareholders' equity in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 19.82 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $137.8M | +2366.6% |
| FY2024 | $5.6M | -44.6% |
| FY2023 | $10.1M | -20.1% |
| FY2019 | $12.6M | +31.3% |
| FY2018 | $9.6M | +239.8% |
| FY2017 | $2.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026